Literature DB >> 24275893

Mesenchymal stromal cells for organ transplantation: different sources and unique characteristics?

Martin J Hoogduijn1, Michiel G H Betjes, Carla C Baan.   

Abstract

PURPOSE OF THE REVIEW: In this review, recent findings on the effects of tissue and donor origin, culturing conditions and preconditioning regimens on the therapeutic effect of mesenchymal stem cells (MSC) in organ transplantation are discussed and the importance of understanding the characteristics of MSC for developing efficient therapy is stressed. RECENT
FINDINGS: MSC research in organ transplantation is currently moving from safety-feasibility studies to efficacy studies and finding the optimal MSC for therapy is therefore highly relevant. Although sharing basic properties, there are subtle differences between MSC from different tissue sources that may affect their efficacy. Furthermore, the use of MSC from diseased organ recipients, donor or third party may affect their therapeutic effect. The importance of these differences in MSC properties may however be overshadowed by the impact of culture conditions on MSC. Culture conditions dramatically change the characteristics of MSC, and this situation can be exploited by exposing MSC to preconditioning treatment to bring about the desired properties in MSC. As MSC appear to be short-lived after infusion, the specific characteristics of MSC are mostly relevant for short-term interactions between MSC and host cells, which will subsequently take over the effects of MSC. The multiple effects of MSC are by no means unique, but the full spectrum of the effects in combination with their easy isolation and expansion make MSC a suitable cell type for therapy.
SUMMARY: Tissue source, donor source and culture conditions affect the phenotypical and functional properties of MSC. The efficacy of MSC therapy will therefore depend on the source and manipulation of MSC.

Entities:  

Mesh:

Year:  2014        PMID: 24275893     DOI: 10.1097/MOT.0000000000000036

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  28 in total

Review 1.  Why some organ allografts are tolerated better than others: new insights for an old question.

Authors:  Travis D Hull; Gilles Benichou; Joren C Madsen
Journal:  Curr Opin Organ Transplant       Date:  2019-02       Impact factor: 2.640

Review 2.  Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease.

Authors:  Raghavan Chinnadurai; Spencer Ng; Vijayakumar Velu; Jacques Galipeau
Journal:  World J Gastroenterol       Date:  2015-04-28       Impact factor: 5.742

3.  In vivo myomaker-mediated heterologous fusion and nuclear reprogramming.

Authors:  Yasuyuki Mitani; Ronald J Vagnozzi; Douglas P Millay
Journal:  FASEB J       Date:  2016-10-17       Impact factor: 5.191

Review 4.  Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?

Authors:  Martha L Arango-Rodriguez; Fernando Ezquer; Marcelo Ezquer; Paulette Conget
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

5.  Dissection of the cord blood stromal component reveals predictive parameters for culture outcome.

Authors:  Mario Barilani; Cristiana Lavazza; Mariele Viganò; Tiziana Montemurro; Valentina Boldrin; Valentina Parazzi; Elisa Montelatici; Mariacristina Crosti; Monica Moro; Rosaria Giordano; Lorenza Lazzari
Journal:  Stem Cells Dev       Date:  2015-01-01       Impact factor: 3.272

6.  Human renal tubular epithelial cells suppress alloreactive T cell proliferation.

Authors:  M W H J Demmers; S S Korevaar; M Roemeling-van Rhijn; T P P van den Bosch; M J Hoogduijn; M G H Betjes; W Weimar; C C Baan; A T Rowshani
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

7.  Comparison of Adipose-Derived and Bone Marrow Mesenchymal Stromal Cells in a Murine Model of Crohn's Disease.

Authors:  Minghao Xie; Huabo Qin; Qianxin Luo; Xiaosheng He; Xiaowen He; Ping Lan; Lei Lian
Journal:  Dig Dis Sci       Date:  2016-04-23       Impact factor: 3.199

Review 8.  Mesenchymal stromal cell therapy for the treatment of intestinal ischemia: Defining the optimal cell isolate for maximum therapeutic benefit.

Authors:  Dominique L Doster; Amanda R Jensen; Sina Khaneki; Troy A Markel
Journal:  Cytotherapy       Date:  2016-10-10       Impact factor: 5.414

Review 9.  Efficacy of Mesenchymal Stromal Cells for Fistula Treatment of Crohn's Disease: A Systematic Review and Meta-Analysis.

Authors:  Yantian Cao; Zhen Ding; Chaoqun Han; Huiying Shi; Lianlian Cui; Rong Lin
Journal:  Dig Dis Sci       Date:  2017-02-06       Impact factor: 3.199

Review 10.  Advances in therapeutic applications of extracellular vesicles.

Authors:  Oscar P B Wiklander; Meadhbh Á Brennan; Jan Lötvall; Xandra O Breakefield; Samir El Andaloussi
Journal:  Sci Transl Med       Date:  2019-05-15       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.